Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia
Aim. To study the efficiency of IL-6 inhibitor olokizumab in suppressing the inflammation and improving treatment outcomes in patients with moderate COVID-19 pneumonia. Materials and Methods. We enrolled 48 patients with confirmed COVID-19 pneumonia who had indications for the treatment with olokizu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Kemerovo State Medical University
2020-12-01
|
| Series: | Фундаментальная и клиническая медицина |
| Subjects: | |
| Online Access: | https://fcm.kemsmu.ru/jour/article/view/328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850064795031568384 |
|---|---|
| author | N. G. Ganyukova M. I. Likstanov M. V. Kosinova I. N. Kushnir V. G. Moses K. B. Moses |
| author_facet | N. G. Ganyukova M. I. Likstanov M. V. Kosinova I. N. Kushnir V. G. Moses K. B. Moses |
| author_sort | N. G. Ganyukova |
| collection | DOAJ |
| description | Aim. To study the efficiency of IL-6 inhibitor olokizumab in suppressing the inflammation and improving treatment outcomes in patients with moderate COVID-19 pneumonia. Materials and Methods. We enrolled 48 patients with confirmed COVID-19 pneumonia who had indications for the treatment with olokizumab. Treatment group (n = 29) included patients who received a single subcutaneous injection of olokizumab (0.4 mL, 160 mg/mL) while placebo group (n = 19) included those who did not receive the drug because of contraindications. Inflammatory markers (C-reactive protein, white blood cell count, lymphocyte count, ferritin and D-dimer) have been evaluated on the 1st and the 5th day after the administration of olokizumab. Efficiency of olokizumab was assessed by the treatment outcome and suppression of cytokine storm. Results. At the 5th day, SpO2 was 90% (88; 92-93) in both groups, yet none of the patients in the treatment group required a mechanical ventilation, in contrast to 21.1% patients in the placebo group (p = 0.001). Inflammatory parameters were also reduced in the treatment group according to the measurements of serum C-reactive protein (5.6 (1.8;13.5) and 23 (17;92.5) mg/L in the treatment and placebo group, respectively, p = 0.0002) and white blood cell count (5.9 (4.8;6.2) and 7.6 (6.6;12 )*109 /L in the treatment and placebo group, respectively, p=0.03). No statistically significant differences were registered regarding serum ferritin (325 (200; 700) and 215 (186; 526) ng/mL, p = 0.41), D-dimer (827 (378; 1940) and 1464 (677; 4600) ng FEU/mL, p = 0.16) and lymphocyte count (1.3 (0.8; 2.1) and 1.5 (1; 2.1)*109 /L, p =0.44). Death was registered in 3.5% and 21.1% of patients in the treatment and placebo group, respectively, (p = 0.05). Conclusion. Olokizumab ameliorated the progression of COVID-19 pneumonia, improved treatment outcomes and reduced systemic inflammation. |
| format | Article |
| id | doaj-art-211dadae959248f4977ef4d2b9996e1d |
| institution | DOAJ |
| issn | 2500-0764 2542-0941 |
| language | Russian |
| publishDate | 2020-12-01 |
| publisher | Kemerovo State Medical University |
| record_format | Article |
| series | Фундаментальная и клиническая медицина |
| spelling | doaj-art-211dadae959248f4977ef4d2b9996e1d2025-08-20T02:49:12ZrusKemerovo State Medical UniversityФундаментальная и клиническая медицина2500-07642542-09412020-12-015481310.23946/2500-0764-2020-5-4-8-13223Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumoniaN. G. Ganyukova0M. I. Likstanov1M. V. Kosinova2I. N. Kushnir3V. G. Moses4K. B. Moses5Belyaev Kuzbass Clinical HospitalBelyaev Kuzbass Clinical HospitalBelyaev Kuzbass Clinical HospitalBelyaev Kuzbass Clinical HospitalKemerovo State Medical University; Belyaev Kuzbass Clinical HospitalKemerovo State Medical UniversityAim. To study the efficiency of IL-6 inhibitor olokizumab in suppressing the inflammation and improving treatment outcomes in patients with moderate COVID-19 pneumonia. Materials and Methods. We enrolled 48 patients with confirmed COVID-19 pneumonia who had indications for the treatment with olokizumab. Treatment group (n = 29) included patients who received a single subcutaneous injection of olokizumab (0.4 mL, 160 mg/mL) while placebo group (n = 19) included those who did not receive the drug because of contraindications. Inflammatory markers (C-reactive protein, white blood cell count, lymphocyte count, ferritin and D-dimer) have been evaluated on the 1st and the 5th day after the administration of olokizumab. Efficiency of olokizumab was assessed by the treatment outcome and suppression of cytokine storm. Results. At the 5th day, SpO2 was 90% (88; 92-93) in both groups, yet none of the patients in the treatment group required a mechanical ventilation, in contrast to 21.1% patients in the placebo group (p = 0.001). Inflammatory parameters were also reduced in the treatment group according to the measurements of serum C-reactive protein (5.6 (1.8;13.5) and 23 (17;92.5) mg/L in the treatment and placebo group, respectively, p = 0.0002) and white blood cell count (5.9 (4.8;6.2) and 7.6 (6.6;12 )*109 /L in the treatment and placebo group, respectively, p=0.03). No statistically significant differences were registered regarding serum ferritin (325 (200; 700) and 215 (186; 526) ng/mL, p = 0.41), D-dimer (827 (378; 1940) and 1464 (677; 4600) ng FEU/mL, p = 0.16) and lymphocyte count (1.3 (0.8; 2.1) and 1.5 (1; 2.1)*109 /L, p =0.44). Death was registered in 3.5% and 21.1% of patients in the treatment and placebo group, respectively, (p = 0.05). Conclusion. Olokizumab ameliorated the progression of COVID-19 pneumonia, improved treatment outcomes and reduced systemic inflammation.https://fcm.kemsmu.ru/jour/article/view/328covid-19pneumoniail-6 inhibitors |
| spellingShingle | N. G. Ganyukova M. I. Likstanov M. V. Kosinova I. N. Kushnir V. G. Moses K. B. Moses Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia Фундаментальная и клиническая медицина covid-19 pneumonia il-6 inhibitors |
| title | Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia |
| title_full | Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia |
| title_fullStr | Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia |
| title_full_unstemmed | Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia |
| title_short | Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia |
| title_sort | efficiency of il 6 inhibitor olokizumab in suppressing inflammation in patients with moderate covid 19 pneumonia |
| topic | covid-19 pneumonia il-6 inhibitors |
| url | https://fcm.kemsmu.ru/jour/article/view/328 |
| work_keys_str_mv | AT ngganyukova efficiencyofil6inhibitorolokizumabinsuppressinginflammationinpatientswithmoderatecovid19pneumonia AT milikstanov efficiencyofil6inhibitorolokizumabinsuppressinginflammationinpatientswithmoderatecovid19pneumonia AT mvkosinova efficiencyofil6inhibitorolokizumabinsuppressinginflammationinpatientswithmoderatecovid19pneumonia AT inkushnir efficiencyofil6inhibitorolokizumabinsuppressinginflammationinpatientswithmoderatecovid19pneumonia AT vgmoses efficiencyofil6inhibitorolokizumabinsuppressinginflammationinpatientswithmoderatecovid19pneumonia AT kbmoses efficiencyofil6inhibitorolokizumabinsuppressinginflammationinpatientswithmoderatecovid19pneumonia |